2.31
-0.01 (-0.43%)
| Previous Close | 2.32 |
| Open | 2.42 |
| Volume | 1,566,694 |
| Avg. Volume (3M) | 1,302,722 |
| Market Cap | 422,009,440 |
| Price / Book | 4.06 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2026 |
| Diluted EPS (TTM) | -1.61 |
| Total Debt/Equity (MRQ) | 0.41% |
| Current Ratio (MRQ) | 8.98 |
| Operating Cash Flow (TTM) | -199.43 M |
| Levered Free Cash Flow (TTM) | -108.00 M |
| Return on Assets (TTM) | -48.51% |
| Return on Equity (TTM) | -79.05% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Neumora Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -2.5 |
| Average | -0.88 |
|
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 27.57% |
| % Held by Institutions | 60.62% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Wellcome Trust Ltd (The) As Trustee Of The Wellcome Trust | 31 Mar 2026 | 3,309,123 |
| Lunate Capital Ltd | 31 Mar 2026 | 2,124,143 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |